20th Apr 2026 14:28
Tristel plc
("Tristel" or the "Company")
Holding(s) in Company
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it was notified on 17 April 2026 that, as of 16 April 2026, Artemis Investment Management LLP, holds, 3.00216 per cent. of the Company's issued share capital.
For further information please contact:
Tristel plc | Via Walbrook PR | |||
Matt Sassone, Chief Executive Officer | www.investors.tristel.com | |||
Anna Wasyl, Chief Financial Officer | ||||
Walbrook PR Ltd | Tel: 020 7933 8780 or [email protected] | |||
Paul McManus / Lianne Applegarth / Anna Dunphy | Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 | |||
Cavendish Capital Markets Ltd | Tel: 020 7220 0500 | |||
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance) | ||||
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) | ||||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
Related Shares:
Tristel